Otros trastornos
Capítulo H.4
Editores: Laura Borredá Belda, Matías Irarrázaval & Andres Martin
Traductores: Sara Diego Castaño, Laura Álvarez Bravos, Rebeca Santonja & Beatriz Ortega
Autres troubles
Chapitre H.4
Autres troubles
Chapitre H.3
Edition en français Traduction : Sevan Minassian Sous la direction de : Priscille Gérardin Avec le soutien de la SFPEADA
Naicker et al. BMC Palliative Care (2016) 15:41 DOI 10.1186/s12904-016-0114-7
La pratique infirmière avancée (PIA), telle qu’évoquée dans le présent document, se réfère aux services et
aux interventions de santé renforcés et étendus, assurés par des infirmières qui, grâce à des compétences avancées, influent sur les résultats des soins de santé cliniques ...et dispensent des services de santé directs à la personne, aux familles et aux collectivités (CNA, 2019; Hamric et Tracy, 2019). Une infirmière de pratique avancée (IPA) a acquis, grâce à une formation complémentaire, une base de connaissances spécialisées, des capacités perfectionnées en matière de prise de décision et des compétences cliniques pour une pratique infirmière plus étendue, dont les caractéristiques dépendent du contexte dans lequel elle est accréditée
à exercer ses fonctions (CII, 2008a). L’infirmière clinicienne spécialisée (ICS) et l’infirmière praticienne (IP)
sont les deux catégories d’IPA les plus généralement
more
The present booklet is about gender-responsive substance abuse treatment services for women. It is part of the United Nations Office on Drugs and Crime (UNODC) project to develop tools to support the development and improvement of substance abuse treatment services, based on evidence from the litera...ture and case studies that illustrate practical experiences and lessons learned in providing substance abuse treatment services in various regions of the world.
more
9 June 2021
Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth G...LASS report.
The fourth GLASS report summarizes the 2019 data reported to WHO in 2020. It includes data on AMC surveillance from 15 countries and AMR data on 3 106 602 laboratory-confirmed infections reported by 24 803 surveillance sites in 70 countries, compared to the 507 923 infections and 729 surveillance sites reporting to the first data call in 2017.
The report also describes developments over the past years of GLASS and other AMR surveillance programmes led by WHO, including resistance to anti-human immunodeficiency virus and anti-tuberculosis medicines, antimalarial drug efficacy.
more
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
The document contains preliminary report on all aspects of WHO’s response in the Ebola outbreak. WHO Member States will discuss the report at the sixty-eighth World Health Assembly.
Advising principles. The purpose of this document is to support competent authorities in charge of IHR implementation to improve national capacities for the prevention, detection and control of events, by strengthening communications and coordination between points of entry and the national health s...urveillance system
more
Barbados currently has a rudimentary framework and capacity to address the issue of antimicrobial resistance. There however needs to be coordination of efforts and improvement in areas where gaps have been identified.Actions required include improved antibiotic stewardship in healthcare settings, pr...evention of the spread of drug-resistant organisms//bacteria, elimination of the use of medically-important antibiotics for growth promotion in food animals, and expanded surveillance for drug-resistant bacteria in humans and animals.
The National Action Plan will provide the roadmap to guide Barbados in the effort to address the urgent and serious threat of AMR and will be organized around three goals for collaborative action.
more
The Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (the framework) aims to provide values and principles, tools and mechanisms to support Member States and key stakeholders to mitigate and prevent biorisks and govern dual-u...se research.
The framework adopts the One health approach and focuses on the role that responsible life sciences research can play in preventing and mitigating risks caused by accidents, inadvertent or deliberate misuse with the intention to cause harm to humans, nonhuman animals, plants and agriculture, and the environment.
more
Risk assessment and priority interventions
Second Edition
AIDS Medicines and diagnostics services
July 2015